Moderna mRNA-1273 vs Gilead Veklury vs Vaxart Oral Vaccine vs Sorrento T-VIVA-19. Which is Effective and Available Now?

Operation Warp Speed has pushed Moderna, Vaxart, Gilead, Sanofi, GSK to develop vaccines against COVID-19 faster. There are developed from scratch and already existing vaccines that are under tests.

Moderna mRNA-1273

On July 27th mRNA-1273 has entered phase 3 clinical study. Despite that, the U.S government orders 100 million doses for $1.525 billion even before approving the drug. It means officials are sure about reliability of mRNA-1273 but the time will show.

Vaxart Oral Vaccine

Vaxart is yet to start the development of its oral vaccine for COVID-19 patients. By having this drug Vaxart could treat a massive population while injection method takes longer time for infected people.

Gilead Veklury (Remdesivir)

One of the well-established biotech companies Gilead already has an existing vaccine for COVID-19 patients, Remdesivir or commercially called Veklury has been under clinical trials for a long time. There are mixed results from the tests. Perhaps Gilead is upgrading it so the patients may get rid of the virus fast.

Related:  Sanofi (SNY) and GlaxoSmithKline (GSK) To Surge Amid Receiving $2.1 Billion To Fight COVID-19. Here is Why
Sorrento T-VIVA-19

In July Sorrento informed that tests on mice showed that T-VIVA-19 produced neutralizing antibodies. Safety trials of the drug are not finished yet. Perhaps in quarter four Sorrento may present the prepared version of the T-VIVA-19.

There is no COVID-19 vaccine that finished all safety trials on the human body. Therefore we can’t be sure that particular company already has a complete drug to end the pandemic. However, the biotech stocks keep rising due to a big hope of crowds in finishing the extended pandemic.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life